According to a new report published by Allied Market Research, titled, Asia-Pacific IVF Services Market, by Cycle Type, and End User: Opportunity Analysis and Industry Forecast, 2018-2028" the market generated $2,527 million in 2014 and is projected to reach $13,669 million by 2028, growing at a CAGR of 12.4% from 2018 to 2028.
In vitro fertilization (IVF) is a type of assisted reproductive technology in which the ovum is artificially fertilized in laboratory settings and then implanted into the uterus. IVF is one of the widely used treatments, which assisted couples with infertility problems, single mothers, and the LGBT community to procreate. Increase in infertility rate, rise in trend of delayed pregnancies, surge in IVF success rate, and growth in disposable income in Asia-Pacific region drive the growth of the IVF services market. However, the market growth is restricted by complications associated with IVF treatment, and low awareness level for IVF in some under developed regions.
Based on cycle-type, the fresh cycle (non-donor) segment is major revenue contributor and is expected to dominate the market during the forecast period.
Depending on end user, the Asia-Pacific IVF services market is dominated by the fertility clinics segment and is estimated to continue this trend during the forecast period, due to low cost of treatment and increase in number of fertility clinics.
Key Findings of the Asia-pacific IVF Services Market:
- Fresh IVF cycle (non-donor) segment is expected to grow at a significant CAGR of 12.9% (in terms of value) from 2018 to 2028
- Japan generated the highest revenue in the Asia-Pacific IVF services market in 2017 accounting for nearly half of the market share in 2017
- Japan witnessed the highest number of IVF treatments accounting for nearly two-fifths of the total cycles in 2017 and is expected to remain so throughout the forecast period
- India is expected to register the highest CAGR of 15.3% (in terms of value) throughout the forecast period
The list of key players profiled in this report include Apollo Hospitals Dhaka, Australian Concept Infertility Medical Center (ACIMC), Bahosi Fertility Centre, Bangkok IVF center, Bloom Fertility and Healthcare, Bloom Fertility Center, Bourn Hall Fertility Center, Bumrungrad International Hospital, Center for Advanced Reproductive Medicine and Infertility, CHA Fertility Center, Chennai Fertility Center, Cloudnine Fertility, Damai Service Hospital, Fatemieh Infertility Center, Fertility Associates, Fertility Centre Nepal (Part of Wecare Health Services, India), Fertility First, Flinders Reproductive Medicine Pty Ltd, Genea Oxford Fertility Limited, IHH Healthcare Berhad, IVF NAMBA Clinic, IVF Sri Lanka Life Plus (Pvt) Ltd, IVF Van Hanh, KL Fertility & Gynecology Centre, Lanka Hospitals, LIFE - Lahore Institute of Fertility & Endocrinology, Lotus Fertility Clinic, Manipal Fertility, Maria Fertility Hospital, MEHR IVF Clinic, Monash IVF Wesley Hospital Auchenflower, Morpheus Life Sciences Pvt. Ltd., Morula IVF, National University Hospital, Nepal International Fertility Centre, Oak Medical Group/Oak Clinic, Raffles Medical Group, Repromed, RSUP Dr. Hasan Sadikin Bandung, SAFE Fertility Center, Sanno Hospital, Saqib Fertility & IVF Center Mid City Hospital, Shanghai Ji Ai Genetics & IVF Institute, Shanghai, United Family Hospital, Southend Fertility and IVF, Superior A.R.T Myanmar, Thomson Medical Pte. Ltd., TMC Fertility Centre, Tu Du Hospital, Victory A.R.T. Laboratory Phils., Inc., and Virtus Health.